
Xavier Matias-Guiu Guia
Grau: Doctor/a
973 705 340
fjmatiasguiu.lleida.ics(ELIMINAR)@gencat.cat
ResearcherID: http://www.researcherid.com/rid/C-3039-2009
Grups
Publicacions
-
Llauradó M; Majem B; Altadill T; Lanau L; Castellví J; Sánchez-Iglesias JL; Cabrera S; de la Torre J; Díaz-Feijoo B; Pérez-Benavente A; Colás E; Olivan M; Doll A; Alameda F; Matias-Guiu X; Moreno-Bueno G; Carey M; Del Campo JM; Gil-Moreno A; Reventós J; Rigau M
MicroRNAs as prognostic markers in ovarian cancer
MOLECULAR AND CELLULAR ENDOCRINOLOGY 390 73-84. .
-
Bergadà L; Pallares J; Arcidiacono MV; Cardus A; Santacana M; Valls J; Cao G; Fernàndez E; Dolcet X; Dusso AS; Matias-Guiu X
Role of local bioactivation of vitamin D by CYP27A1 and CYP2R1 in the control of cell growth in normal endometrium and endometrial carcinoma
LABORATORY INVESTIGATION 94 608-622. .
-
Muniesa, M.J.; González, S.; Buetas, P.; López, S.; Sánchez, C.; Matias-Guiu, X.
Estudio del epitelio conjuntival de las ampollas filtrantes mediante citología de impresión.
Archivos De La Sociedad Española De Oftalmología 89 216-221. .
-
Novell, A; Martinez-Alonso, M; Mira, M; Tarragona, J; Salud, A; Matias-Guiu, X
Prognostic value of c-FLIPL/s, HIF-1 alpha, and NF-kappa beta in stage II and III rectal cancer
VIRCHOWS ARCHIV 464 645-654. .
-
Moran S; Vizoso M; Martinez-Cardús A; Gomez A; Matías-Guiu X; Chiavenna SM; Fernandez AG; Esteller M
Validation of DNA methylation profiling in formalin-fixed paraffin-embedded samples using the Infinium HumanMethylation450 Microarray
EPIGENETICS 9 829-833. .
-
Micci F; Gorunova L; Gatius S; Matias-Guiu X; Davidson B; Heim S; Panagopoulos I
MEAF6/PHF1 is a recurrent gene fusion in endometrial stromal sarcoma
CANCER LETTERS 347 75-78. .
-
Croner RS; Geppert CI; Bader FG; Nitsche U; Späth C; Rosenberg R; Zettl A; Matias-Guiu X; Tarragona J; Güller U; Stürzl M; Zuber M
Molecular staging of lymph node-negative colon carcinomas by one-step nucleic acid amplification (OSNA) results in upstaging of a quarter of patients in a prospective, European, multicentre study
BRITISH JOURNAL OF CANCER 110 2544-2550. .
-
Espinosa, I; Catasus, L; D' Angelo E; Mozos, A; Pedrola, N; Bertolo, C; Ferrer, I; Zannoni, GF; West, RB; van de Rijn, M; Matias-Guiu, X; Prat, J
Stromal signatures in endometrioid endometrial carcinomas
Modern Pathology 27 631-639. .
-
Eritja N; Domingo M; Dosil MA; Mirantes C; Santacana M; Valls J; Llombart-Cussac A; Matias-Guiu X; Dolcet X
Combinatorial Therapy Using Dovitinib and ICI182.780 (Fulvestrant) Blocks Tumoral Activity of Endometrial Cancer Cells
MOLECULAR CANCER THERAPEUTICS 13 776-787. .
-
Bergadà L; Yeramian A; Sorolla A; Matias-Guiu X; Dolcet X
Antioxidants Impair Anti-Tumoral Effects of Vorinostat, but Not Anti-Neoplastic Effects of Vorinostat and Caspase-8 Downregulation
PLOS ONE 9 -. .
-
Matias-Guiu X; Davidson B
Prognostic biomarkers in endometrial and ovarian carcinoma
VIRCHOWS ARCHIV 464 315-331. .
-
Matias-Guiu X; De Lellis R
Medullary Thyroid Carcinoma: a 25-Year Perspective
ENDOCRINE PATHOLOGY 25 21-29. .
Projectes
- Unravelling the molecular and phenotypic complexity of endometriosis through new models and omics integration: towards a personalized clinical management
- Homologous recombination deficiency in high-grade endometrial cancers. Biomarkers and impact of intratumor heterogeneity.
- EPH Receptor Signaling in Endometrial Cancer
- Ajuts per a la contractació de personal investigador novell (FI)
- Personalized Immunotherapy for Endometrial Cancer; Acronym: ExCITE (Endometrial Cancer Immunotherapy)
- "Multi-Omics data for Cancer Research and the Development of New Diagnostics and Therapies"
- EFFICACY: Nuevas estrategias para incrementar efectividad de los tratamientos con ABTL0812
- Perfiles epigenéticos asociados a patrones de metastasis en cáncer de endometrio
- CONTRACTES D'INCORPORACIO DE CIENTIFICS I TECNOLEGS: INCORPORACIO D'UNA DOCTORA PER A L'ACCIO ANTITUMORAL DELS CANNABINOIDES EN EL CARCINOMA D'ENDOMETRI
- DISCOVERY, VALIDATION AND IMPLEMENTATION OF BIOMARKERS FOR PRECISION ONCOLOGY
- Desarrollo de nuevas aproximaciones en el manejo individualizado de pacientes con cancer ginecológico (PREDICTGYN)
- VALIDACION DE ANEXINA 2 COMO PREDICTOR DE RECIDIVA EN EL CANCER DE ENDOMETRIO. DISEÑO DE NUEVAS ESTRATEGIAS TERAPEUTICAS. ANXARECU